The aim of the present study was to develop a sustained release bio-adhesive matrix based Gliclazide tablet to match the in-vitro and ex-vivo experimental profile, and can be used to the treatment of Type II Diabetes Mellitus. It will be expected that single Gliclazide tablet reduce glycosylated hemoglobin and overcoming individual large fluctuation of oral bioavailability. Eleven types of tablets were formulated by wet granulation technique which contains 30 mg of Gliclazide and different concentrations of diverse bio-adhesive polymers which conforming to the USP/BP monograph. The prepared tablets were evaluated for their physicochemical parameters, bio-adhesive behavior and also in-vitro release pattern and ex-vivo residence time. Formulated F-6 tablet (300 mg) contains 30 mg Gliclazide, 90 mg Carbopol 974P NF, 155 mg Lactose, 15 mg Povidone, 5 mg Magnesium Stearate and 5 mg Talc. Carbopol based F-6 tablets showed highest significance adherence (164.1 gm) property and also exhibited greater than 300 minutes ex-vivo residence time. In-vitro release pattern of F-6 formulation was 44.74% (Mean Dissolution Time 52.86 hrs which was studied for 8 hours in phosphate buffer media at pH 7.4. Different kinetic models including zero order, first order, Higuchi and Korsmeyer pattern were applied to evaluate drug release behavior. Zero order and Korsmeyer pattern indicated most appropriate model for describing the release profile of F-6 formulation. The drug release mechanism was consequently found to be diffusion, swelling and erosion. The results point out that Carbopol 974P NF bio-adhesive matrix Gliclazide tablets have marked sustained release properties.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.